Breaking News: FDA Grants Orphan Drug Designation to Jaguar Health’s Crofelemer for Cholera-Related Diarrhea Treatment
Description:
World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide. Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae. Crofelemer previously granted orphan-drug designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome and microvillus inclusion disease. SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2024 / Jaguar Health (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to crofelemer, the company’s novel plant-based prescription drug, for treatment of diarrhea in cholera. “We are very pleased that crofelemer has been granted orphan-drug designation for this important indication,” said Steven King, PhD, Jaguar’s Chief Sustainable Supply, Ethnobotanical Research & IP Officer.
Effect on Me:
This news could potentially have a significant impact on individuals like yourself who may be at risk of cholera-related diarrhea. The FDA’s orphan drug designation for crofelemer means that there is now a specialized treatment option available for this serious condition. If you or a loved one ever face cholera-related diarrhea, having access to a targeted treatment like crofelemer could greatly improve outcomes and quality of life.
Effect on the World:
The FDA’s orphan drug designation for crofelemer has the potential to benefit millions of individuals worldwide who are affected by cholera. With millions of cases and thousands of deaths each year globally, having a specific treatment like crofelemer could help reduce the impact of cholera on a global scale. This designation marks a step forward in addressing the global health crisis posed by cholera and could lead to improved management and prevention strategies.
Conclusion:
In conclusion, the FDA granting orphan drug designation to Jaguar Health’s crofelemer for cholera-related diarrhea treatment is a significant development in the field of healthcare. This specialized treatment offers hope for individuals affected by cholera and has the potential to make a positive impact both on an individual level and on a global scale. The recognition of crofelemer as an orphan drug underscores the importance of targeted therapies in addressing serious and life-threatening conditions like cholera. Overall, this news highlights the progress being made in medical research and the ongoing efforts to improve health outcomes for people around the world.
